15.83
-0.16(-1.00%)
Currency In USD
| Previous Close | 15.99 |
| Open | 15.74 |
| Day High | 16.41 |
| Day Low | 15.57 |
| 52-Week High | 29.79 |
| 52-Week Low | 11.56 |
| Volume | 192,469 |
| Average Volume | 327,631 |
| Market Cap | 406.65M |
| PE | -4.9 |
| EPS | -3.23 |
| Moving Average 50 Days | 16.89 |
| Moving Average 200 Days | 19.42 |
| Change | -0.16 |
If you invested $1000 in Tourmaline Bio, Inc. (TRML) since IPO date, it would be worth $219.31 as of July 02, 2025 at a share price of $15.83. Whereas If you bought $1000 worth of Tourmaline Bio, Inc. (TRML) shares 3 years ago, it would be worth $1,229.04 as of July 02, 2025 at a share price of $15.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
May 02, 2025 11:30 AM GMT
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinica
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
GlobeNewswire Inc.
Mar 03, 2025 12:15 PM GMT
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune a